STRUCTURE THERAPEUTICS INC (GPCR) Stock Overview
USA - NASDAQ:GPCR - US86366E1064 - ADR
GPCR Key Statistics, Chart & Performance
The current stock price of GPCR is 21.79 USD. In the past month the price increased by 9.17%. In the past year, price decreased by -48.02%.
GPCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.35 | 723.77B | ||
| JNJ | JOHNSON & JOHNSON | 17.65 | 424.98B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.48 | 254.16B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.47 | 240.47B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.87 | 237.68B | ||
| MRK | MERCK & CO. INC. | 10.53 | 202.54B | ||
| PFE | PFIZER INC | 7.05 | 135.88B | ||
| SNY | SANOFI-ADR | 10.46 | 114.29B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.89 | 94.32B | ||
| GSK | GSK PLC-SPON ADR | 8.76 | 80.68B | ||
| ZTS | ZOETIS INC | 23.71 | 65.35B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 52.14 | 47.75B |
Related stock screener links
About GPCR
Company Profile
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 199 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Company Info
STRUCTURE THERAPEUTICS INC
611 Gateway Blvd Suite 223
South San Francisco CALIFORNIA US
Employees: 199
Phone: 16282299277
STRUCTURE THERAPEUTICS INC / GPCR FAQ
What is the stock price of STRUCTURE THERAPEUTICS INC today?
The current stock price of GPCR is 21.79 USD. The price increased by 7.87% in the last trading session.
What is the ticker symbol for STRUCTURE THERAPEUTICS INC stock?
The exchange symbol of STRUCTURE THERAPEUTICS INC is GPCR and it is listed on the Nasdaq exchange.
On which exchange is GPCR stock listed?
GPCR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for STRUCTURE THERAPEUTICS INC stock?
20 analysts have analysed GPCR and the average price target is 77.44 USD. This implies a price increase of 255.37% is expected in the next year compared to the current price of 21.79. Check the STRUCTURE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is STRUCTURE THERAPEUTICS INC worth?
STRUCTURE THERAPEUTICS INC (GPCR) has a market capitalization of 1.26B USD. This makes GPCR a Small Cap stock.
How many employees does STRUCTURE THERAPEUTICS INC have?
STRUCTURE THERAPEUTICS INC (GPCR) currently has 199 employees.
What are the support and resistance levels for STRUCTURE THERAPEUTICS INC (GPCR) stock?
STRUCTURE THERAPEUTICS INC (GPCR) has a support level at 21.6 and a resistance level at 22.08. Check the full technical report for a detailed analysis of GPCR support and resistance levels.
Should I buy STRUCTURE THERAPEUTICS INC (GPCR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GPCR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GPCR, evaluating the profitability, health, valuation and growth aspects
- STRUCTURE THERAPEUTICS INC (GPCR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- STRUCTURE THERAPEUTICS INC (GPCR) Sales and EPS estimates to see what analysts future expectations are.
- STRUCTURE THERAPEUTICS INC (GPCR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- STRUCTURE THERAPEUTICS INC (GPCR) Insider and Institutional Ownership to learn about the owners and their transactions.
- STRUCTURE THERAPEUTICS INC (GPCR) Stock Chart to make your own analysis
- STRUCTURE THERAPEUTICS INC (GPCR) Latest news and press-releases to stay up to date.
Does STRUCTURE THERAPEUTICS INC (GPCR) stock pay dividends?
GPCR does not pay a dividend.
When does STRUCTURE THERAPEUTICS INC (GPCR) report earnings?
STRUCTURE THERAPEUTICS INC (GPCR) will report earnings on 2025-11-11, before the market open.
What is the Price/Earnings (PE) ratio of STRUCTURE THERAPEUTICS INC (GPCR)?
STRUCTURE THERAPEUTICS INC (GPCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.18).
What is the Short Interest ratio of STRUCTURE THERAPEUTICS INC (GPCR) stock?
The outstanding short interest for STRUCTURE THERAPEUTICS INC (GPCR) is 38.24% of its float. Check the ownership tab for more information on the GPCR short interest.
GPCR Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GPCR. When comparing the yearly performance of all stocks, GPCR is a bad performer in the overall market: 91.41% of all stocks are doing better.
GPCR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GPCR. While GPCR has a great health rating, there are worries on its profitability.
GPCR Financial Highlights
Over the last trailing twelve months GPCR reported a non-GAAP Earnings per Share(EPS) of -3.18. The EPS decreased by -58.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.92% | ||
| ROE | -23.18% | ||
| Debt/Equity | 0 |
GPCR Forecast & Estimates
20 analysts have analysed GPCR and the average price target is 77.44 USD. This implies a price increase of 255.37% is expected in the next year compared to the current price of 21.79.